etiocholanolone has been researched along with Shock, Cardiogenic in 2 studies
Etiocholanolone: The 5-beta-reduced isomer of ANDROSTERONE. Etiocholanolone is a major metabolite of TESTOSTERONE and ANDROSTENEDIONE in many mammalian species including humans. It is excreted in the URINE.
3alpha-hydroxy-5beta-androstan-17-one : An androstanoid that is 5beta-androstane substituted by an alpha-hydroxy group at position 3 and an oxo group at position 17. It is a metabolite of testosterone in mammals.
Shock, Cardiogenic: Shock resulting from diminution of cardiac output in heart disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre-cardiogenic shock (CS)." | 9.51 | Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). ( Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J, 2022) |
| "Istaroxime was shown, in a small study, to increase systolic blood pressure (SBP) in patients with pre-cardiogenic shock (CS) due to acute heart failure (AHF)." | 5.69 | Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock. ( Adamo, M; Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Pagnesi, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J, 2023) |
| "We examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre-cardiogenic shock (CS)." | 5.51 | Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). ( Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Metra, M | 2 |
| Chioncel, O | 2 |
| Cotter, G | 2 |
| Davison, B | 2 |
| Filippatos, G | 2 |
| Mebazaa, A | 2 |
| Novosadova, M | 2 |
| Ponikowski, P | 2 |
| Simmons, P | 2 |
| Soffer, J | 2 |
| Simonson, S | 2 |
| Pagnesi, M | 1 |
| Adamo, M | 1 |
2 trials available for etiocholanolone and Shock, Cardiogenic
| Article | Year |
|---|---|
Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC).
Topics: Cardiotonic Agents; Double-Blind Method; Etiocholanolone; Heart Failure; Humans; Shock, Cardiogenic | 2022 |
Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock.
Topics: Double-Blind Method; Etiocholanolone; Heart; Heart Failure; Humans; Shock, Cardiogenic | 2023 |